NewGen Provides Business Update
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
NewGen (NIVF) provided a business update covering its NX One platform, K25.ai investment, planned land acquisition and fertility services business. It engaged a consultant for NX One registration with China’s NMPA. Subsidiary Nodexus signed a non-binding research collaboration agreement with Hainan Provincial Cancer Hospital. NewGen completed a 2% equity acquisition in PredicXion Group, which operates K25.ai, and agreed to acquire a further 11%.
Land acquisition deposits for its Ras Al Khaimah project totaled US$4.71 million; no definitive purchase agreement has been executed. IVF and assisted reproductive treatment revenue was broadly flat for the six months ended June 30, 2026 versus 2025. Unaudited balances at June 30, 2026 included approximately US$1.02 million in cash, US$36.4 million in assets and US$26.4 million in equity attributable to company shareholders; total equity including non-controlling interests was US$25.7 million.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Moderate point. Forward-looking: it has not happened yet and may not happen.PredicXion investment includes a completed 2% equity acquisition and an agreement to acquire a further 11%.
- Moderate pointNodexus signed a collaboration agreement with Hainan Provincial Cancer Hospital for NX One validation and clinical research.
- Minor pointNX One registration work advanced through engagement of Shenzhen Siyu as regulatory consultant for China’s NMPA registration.
- Minor pointCytometry intellectual property and equipment acquisition was completed in July 2025.
- Minor pointTotal assets increased versus June 30, 2025, primarily reflecting the cytometry intellectual property acquisition and K25.ai investment.
Negative
- Moderate pointRas Al Khaimah land deposits total US$4.71 million, with no definitive sale and purchase agreement executed. 13× market cap
- Moderate point. Forward-looking: it has not happened yet and may not happen.Hainan hospital collaboration remains non-binding; a definitive agreement is not assured.
Key Figures
- Completed K25.ai equity acquisition
- 2%
- Equity interest in PredicXion Group Limited, which operates K25.ai
- Further K25.ai equity acquisition
- 11%
- Additional equity interests agreed to be acquired
- Land acquisition deposits
- US$4.71 million
- Paid toward land for the Ras Al Khaimah real estate project; definitive sale and purchase agreement not executed
- Cash and cash equivalents
- approximately US$1.02 million
- As of June 30, 2026; unaudited
- Total assets
- approximately US$36.4 million
- As of June 30, 2026; includes US$4.71 million in land acquisition deposits
- Equity attributable to company shareholders
- approximately US$26.4 million
- As of June 30, 2026; unaudited
- Total shareholders’ equity
- approximately US$25.7 million
- Includes non-controlling interests; as of June 30, 2026; unaudited
Historical Context
-
Reported an agreed 13% K25.ai stake at a US$200 million valuation and an expected unrealized gain.
-
Agreed to acquire 3% more at a US$250 million valuation, targeting 13% ownership.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
cytometry medical
microfluidic technical
real-world data medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
BANGKOK, Nov. 16, 2026 (GLOBE NEWSWIRE) -- NewGenIvf Group Limited (Nasdaq: NIVF) (“NewGen” or the “Company”), a technology-driven, diversified growth company, today provided an update on its businesses.
Nodexus and NX One
In July 2025, the Company acquired advanced cytometry intellectual property and equipment. The Company has engaged Shenzhen Siyu Enterprise Management Consulting Co., Ltd. as its regulatory consultant for registration of its NX One microfluidic platform with China’s National Medical Products Administration (“NMPA”).
Nodexus Limited, a wholly-owned Hong Kong subsidiary of the Company, has also signed a non-binding collaboration agreement with Hainan Provincial Cancer Hospital. The agreement records the parties’ intent to collaborate on scientific validation, clinical research and eventual clinical translation of the NX One device in tumor precision diagnosis and treatment and in cell research. The parties intend the collaboration to generate real-world data that may support future clinical validation and clinical application of NX One in China. The agreement is non-binding, and there can be no assurance that a definitive agreement will be entered into.
K25.ai
The Company has completed the acquisition of
Ras Al Khaimah Real Estate Project
The Company has paid deposits of US
IVF Business
Revenue from the Company’s IVF and assisted reproductive treatment business was broadly flat for the six months ended June 30, 2026 compared with the same period in 2025. Management attributes this to lower demand for fertility services across the industry and the effect of the Thailand–Cambodia conflict on patient travel.
Selected Balance Sheet Data (unaudited)
As of June 30, 2026, as reflected in the Company’s unaudited condensed consolidated financial statements for the six months then ended furnished on Form 6-K/A on October 27, 2026:
Cash and cash equivalents were approximately US
Total assets were approximately US
Equity attributable to shareholders of the Company was approximately US
Total shareholders’ equity, including non-controlling interests, was approximately US
The increase in total assets compared with June 30, 2025 primarily reflects the acquisition of the cytometry intellectual property in July 2025 and the Company’s investment in K25.ai.
About NewGen
NewGenIVF Group Limited is a technology-forward, diversified growth company pursuing opportunities across real estate development, digital asset innovation, and reproductive health solutions. The Company operates through NewGenProperty, focused on real estate development projects in Ras Al Khaimah, United Arab Emirates; NewGenDigital, focused on digital asset and decentralized-finance solutions; and NewGenSup, focused on health and longevity products and solutions. NewGenIVF’s legacy business includes IVF and assisted reproductive treatment services across Asia. To learn more, visit www.nivf.global. Information contained on, or accessible through, the Company’s website is not incorporated by reference into this press release.
About Shenzhen Siyu Enterprise Management Consulting Co., Ltd.
Shenzhen Siyu (www.siyu-com.com) is a regulatory consulting firm experienced in China medical device registration. It is serving as full-process regulatory consultant to NewGen for the NX One NMPA registration program, including classification strategy, type-testing coordination, dossier preparation, and regulatory communications.
About Nodexus Limited
Nodexus Limited is a Hong Kong-incorporated company and the developer of the NX One microfluidic platform. It is a subsidiary within the NewGen group focused on advancing the commercialization of NX One for precision oncology applications.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release include, but are not limited to, statements regarding: the Company’s plans to seek registration of NX One with the NMPA and the U.S. Food and Drug Administration; the potential listing of Nodexus Limited under Chapter 18A of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited; the proposed collaboration with Hainan Provincial Cancer Hospital; the completion of the Company’s investment in K25.ai, including payment of the remaining cash consideration; the planned launch of K25.fun; the completion of the land acquisition for the Company’s real estate development project in Ras Al Khaimah; and trends in the Company’s IVF and assisted reproductive treatment business.
These forward-looking statements are based on the Company’s current expectations, estimates, projections and assumptions as of the date of this press release and are subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to differ materially from those expressed or implied. These risks and uncertainties include, among others: the risk that required regulatory registrations for NX One are not obtained or are subject to material delay; the risk that the collaboration with Hainan Provincial Cancer Hospital does not proceed or does not generate supportive data; the risk that the potential listing of Nodexus Limited does not occur, and that any such listing dilutes the Company’s interest in Nodexus Limited; the possibility that the K25.ai transaction is not completed on the terms described or at all, including the Company’s ability to fund its remaining payment obligations; the risk that the carrying value of the Company’s investment in K25.ai is not realized and may be impaired; risks generally associated with strategic investments, including the Company’s limited control over K25.ai’s business; regulatory risk specific to prediction-market and information-market products; the risk that no definitive agreement for the Ras Al Khaimah land is concluded or that the Company’s deposits are not recovered; geopolitical risks, including conflict in the Middle East and between Thailand and Cambodia; changes in demand for fertility services; liquidity and capital requirements risk; and business transformation and execution risk arising from the Company’s ongoing strategic pivot across multiple new business lines. Additional risks are described in the Company’s Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission.
All information provided in this press release is as of the date of this press release. The Company undertakes no obligation to update or revise any forward-looking statements, except as required by applicable securities laws.
Contacts
ICR, LLC
Robin Yang
Phone: +1 (212) 537-3847
Email: Newgenivf.IR@icrinc.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How much of K25.ai operator PredicXion has NewGen acquired?
NewGen completed the acquisition of 2% of PredicXion Group’s equity and agreed to acquire a further 11%. PredicXion operates K25.ai; the additional acquisition was not described as completed.
Why was NewGen’s IVF revenue broadly flat in the first half of 2026?
Management attributes the broadly flat revenue to lower industry demand for fertility services and the Thailand–Cambodia conflict’s effect on patient travel. The comparison covers IVF and assisted reproductive treatment revenue for the six months ended June 30, 2026 against the same period in 2025.
What does NewGen’s NX One hospital collaboration aim to achieve?
The parties intend to generate real-world data that may support future clinical validation and clinical application of NX One in China. The planned work covers tumor precision diagnosis and treatment and cell research. The collaboration agreement is non-binding.